Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.48 |
| ▸ | TACR1 | P25103 | 6/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886658 | 0.85 | TACR1 (0.63) | HSD11B1TACR1CHRM1CHRM3 | |
| SCHEMBL5198260 | 0.83 | TACR1 (0.45) | HSD11B1TACR1CHRM5CHRM1CHRM3 | |
| SCHEMBL2425376 | 0.81 | HSD11B1 (0.58) | HSD11B1TACR1KCNA3OPRM1MEN1 | |
| SCHEMBL19402984 | 0.80 | MAOA (0.54) | TACR1CHRM5CHRM1CHRM3OPRM1 | |
| SCHEMBL23002585 | 0.80 | MAOA (0.61) | HSD11B1KCNA3OPRM1MEN1KMT2A | |
| SCHEMBL13059779 | 0.78 | CYP3A4 (0.56) | HSD11B1OPRM1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3527130 | 0.77 | HSD11B1 (0.42) | HSD11B1TACR1KCNA3OPRM1MEN1 | |
| SCHEMBL14359682 | 0.77 | DPP4 (0.52) | TACR1CHRM1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL12601480 | 0.77 | TACR1 (0.58) | HSD11B1TACR1KCNA3OPRM1ALDH1A1 | |
| SCHEMBL17220377 | 0.76 | SCD5 (0.57) | HSD11B1OPRM1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1714961-B1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1714961-A1 | INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173537-A1 | Indazole compound and pharmaceutical use thereof | CYP3A5, CYP3A43, TP53 | HSD11B1 137/4885TACR1 2343/4885CHRM5 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.